Which longevity startups secured funding?

This blog post has been written by the person who has mapped the longevity tech market in a clean and beautiful presentation

Longevity startups raised $8.49 billion in 2024, more than doubling from the previous year's $3.82 billion across 331 deals.

The funding surge reflects growing investor confidence in cellular reprogramming, senotherapeutics, and AI-driven discovery platforms. Major players like Altos Labs secured $3 billion rounds while specialized funds and corporate VCs actively back breakthrough technologies targeting aging mechanisms at the cellular level.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Which longevity startups raised the largest funding rounds in 2024-2025?

Altos Labs secured the largest longevity funding round ever at $3 billion in their Series A, led by Jeff Bezos, Yuri Milner, and Flagship Pioneering.

ŌURA followed with a $200 million Series D round in October 2024, backed by True, Sequoia, and IVP for their consumer wearable platform. Minovia Therapeutics raised $180 million through a SPAC merger with Launch One Acquisition Corp in June 2025, focusing on mitochondrial augmentation stem cell therapy.

Function Health raised $53 million in Series A funding from Andreessen Horowitz Bio + Health and Khosla Ventures for personalized prevention and health analytics. Rubedo Life Sciences secured $40 million in Series A funding from Khosla Ventures and Ahren Innovation Capital in April 2024, targeting senescent cell clearance with their RLS-1496 small molecule.

Circulate Health raised $12 million in seed funding from Khosla Ventures, Seaside Ventures, and CSC Ventures for therapeutic plasma exchange services. Junevity completed a $10 million seed round in February 2025 from Goldcrest Capital and Godfrey Capital, developing AI-driven transcription factor siRNA therapeutics through their RESET platform.

These funding rounds demonstrate investor confidence in both breakthrough science and consumer health platforms, with valuations reaching unprecedented levels for longevity-focused companies.

Which investors and VCs are most active in longevity startup funding?

Flagship Pioneering and Andreessen Horowitz Bio + Health lead the longevity investment space with broad portfolios spanning discovery platforms, cellular reprogramming, and senotherapeutics.

Khosla Ventures emerged as a key player, leading rounds in Rubedo Life Sciences ($40 million), Circulate Health ($12 million), and Function Health ($53 million). Their focus on breakthrough science and platform technologies positions them as a top-tier longevity investor.

Corporate venture arms from major pharmaceutical companies actively co-invest in translational R&D startups. Pfizer Ventures, Novartis Venture Fund, and Roche Venture Fund participate in Series A and B rounds, bringing strategic value beyond capital through regulatory expertise and commercial partnerships.

Specialized longevity funds include Immortal Dragons based in Singapore, which supports early high-risk moonshot projects, and Healthspan Capital, which backs platform companies across six longevity domains. Longevity.Technology's seed efforts focus on European startups developing aging-related therapeutics.

Notable individual investors include Jeff Bezos and Yuri Milner, who co-led Altos Labs' $3 billion round, and Sam Altman from OpenAI, who invests in healthspan-focused startups through various vehicles.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

What breakthrough technologies are investors backing in longevity?

Partial cellular reprogramming dominates investor interest, with Altos Labs' $3 billion Series A focused on Yamanaka-factor approaches to reset epigenetic age and rejuvenate cells.

Senotherapeutics attract significant funding through companies like Rubedo Life Sciences, which develops small molecules such as RLS-1496 that specifically target and clear senescent cells in dermatology and pulmonary diseases. This approach addresses cellular aging at its source rather than treating symptoms.

AI-driven drug discovery platforms gain traction through startups like Junevity, whose RESET platform uses artificial intelligence and large-scale human data to identify transcription factors for siRNA therapeutics. This technology accelerates the traditional drug development timeline from years to months.

Mitochondrial augmentation represents an emerging area, with Minovia Therapeutics developing MNV-201, which enriches stem cells with allogeneic mitochondria to restore cellular energy production. Their $180 million SPAC demonstrates institutional confidence in mitochondrial therapies.

Consumer health platforms like ŌURA's sleep and recovery monitoring rings bridge the gap between clinical research and everyday health optimization, attracting $200 million in Series D funding from traditional tech investors.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

Which startup received the single largest funding round and what do they do?

Altos Labs secured the largest longevity funding round in history with $3 billion in Series A funding during 2024, dedicated exclusively to partial epigenetic reprogramming research.

The company focuses on using Yamanaka transcription factors to reverse cellular aging by resetting the epigenetic marks that accumulate over time. Their approach differs from traditional drug development by targeting the fundamental mechanisms of aging rather than age-related diseases.

Altos Labs assembled a world-class scientific team including pioneers from Stanford and Harvard who originally developed cellular reprogramming techniques. The company operates multiple research facilities and employs over 300 scientists working on different aspects of cellular rejuvenation.

The $3 billion funding round was led by Jeff Bezos, Yuri Milner, and Flagship Pioneering, reflecting confidence in the company's potential to commercialize breakthrough anti-aging therapies. This represents the largest private investment in longevity research to date.

Their business model focuses on developing therapies that could theoretically extend healthy human lifespan by decades, positioning them as the most ambitious and well-funded company in the longevity space.

Are big tech companies and pharma giants co-investing in longevity startups?

Google-backed Calico continues investing in longevity research through strategic partnerships, while Amazon-backed ventures focus on healthspan technologies and consumer applications.

Pharmaceutical giants participate actively through their venture arms. Pfizer Ventures co-leads Series A and B rounds in translational biotech companies developing aging-related therapeutics. Novartis Venture Fund focuses on platform technologies that could accelerate drug discovery for age-related diseases.

Roche Venture Fund invests in companies developing biomarkers and diagnostics for aging processes, complementing their existing pharmaceutical portfolio. These corporate VCs bring regulatory expertise, clinical trial capabilities, and potential acquisition pathways for successful startups.

Strategic partnerships emerge between longevity startups and established institutions. The Buck Institute partners with Circulate Health on plasma exchange research, while CIRM (California Institute for Regenerative Medicine) provides grants supporting pulmonary senolytics programs.

Tech companies like OpenAI indirectly participate through executives like Sam Altman, who invests personal capital in healthspan startups. This trend indicates growing interest from the technology sector in longevity applications beyond traditional healthcare.

Where geographically is most longevity funding concentrated?

The United States dominates longevity funding with 84% of total deal volume in 2024, hosting 57% of all longevity startups globally according to industry reports.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

If you want to build or invest on this market, you can download our latest market pitch deck here

What funding stages are longevity startups at and how does this affect deal terms?

Seed and pre-seed rounds typically range from $5-20 million, often structured as convertible notes or SAFEs to accelerate early-stage research and platform validation.

Series A rounds average $30-100 million in equity funding with priced rounds becoming standard as companies enter Phase 1/2 clinical trials. Investors price these rounds based on clinical milestones, intellectual property strength, and management team experience.

Series B and C rounds range from $100-250 million, focusing on scaling operations and advancing clinical programs. Companies like Rubedo Life Sciences and Function Health represent typical Series A positioning with strong scientific foundations and clear commercial pathways.

Series D and later-stage mega-rounds exceed $200 million, primarily for consumer health platforms and companies approaching commercialization. ŌURA's $200 million Series D exemplifies this trend, driven by proven market traction and revenue growth.

SPAC transactions like Minovia Therapeutics' $180 million deal provide alternative exit pathways for mature companies seeking public market access. These transactions often include earnout provisions tied to clinical milestones and regulatory approvals.

What equity terms and instruments are longevity startups using?

Convertible notes and SAFEs dominate seed-stage funding, offering founder-friendly terms that defer valuation discussions until Series A rounds when companies have more clinical data.

Series A and beyond typically use equity priced rounds where lead investors set valuations based on comparable transactions, clinical progress, and market potential. Liquidation preferences usually range from 1x to 1.5x non-participating preferred for early-stage companies.

Anti-dilution provisions vary by investor tier, with major VCs securing weighted average broad-based protection while smaller investors accept narrow-based or no anti-dilution rights. Board composition typically gives investors 2-3 seats out of 5-7 total positions.

Employee option pools range from 15-25% of fully diluted shares, with refreshes at each major funding round. Longevity companies often grant larger option pools to attract top scientific talent from academia and established pharma companies.

Revenue-based financing emerges as an alternative for consumer health platforms with predictable cash flows, allowing founders to retain more equity while providing investors with steady returns tied to business performance.

Which startups focus on rejuvenation, cellular reprogramming, and senescence?

Altos Labs leads cellular reprogramming research with their $3 billion Series A focused on partial epigenetic reprogramming using Yamanaka transcription factors to reverse cellular aging.

Rubedo Life Sciences specializes in senotherapeutics with their $40 million Series A funding developing RLS-1496, a small molecule that specifically targets and clears senescent cells. Their approach focuses on dermatology and pulmonary diseases where senescent cell accumulation drives aging-related pathologies.

Junevity develops AI-driven transcription factor siRNA therapeutics through their RESET platform, using artificial intelligence to identify cellular reprogramming targets. Their $10 million seed funding supports research into reversing cellular aging at the transcriptional level.

Turn Biotechnologies, a precursor to several current startups, pioneered mRNA-based cellular reprogramming approaches that influenced current market leaders. Many founders and scientists from Turn now lead other longevity companies developing similar technologies.

Circulate Health targets blood-based aging factors through therapeutic plasma exchange, removing aged proteins and cellular debris that accumulate over time. Their $12 million seed round supports clinical research into "blood cleaning" interventions for longevity.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

If you need to-the-point data on this market, you can download our latest market pitch deck here

Who are the key founders and science teams behind well-funded longevity startups?

Altos Labs assembled a world-class team including pioneers who originally developed cellular reprogramming techniques at Stanford and Harvard, along with former Google Calico scientists who bring computational biology expertise.

Rubedo Life Sciences was founded by Marco Quarta, a former researcher at Turn Biotechnologies who specialized in epigenetics and cellular reprogramming. The team includes UCSF researchers who developed the foundational science behind senescent cell targeting.

Junevity was co-founded by Janine Sengstack from UCSF, focusing on transcriptional reset mechanisms and cellular reprogramming. The company represents a direct spin-out from university research with strong academic foundations.

Circulate Health was co-founded by Brad Younggren, former CEO at the Buck Institute for Research on Aging, and Eric Verdin, a leading researcher in aging biology and metabolism. This combination brings both operational experience and deep scientific expertise.

Function Health was founded by executives with backgrounds in consumer health and preventive medicine, focusing on the intersection of personalized healthcare and longevity optimization rather than pure research.

How much was invested in longevity startups in 2024 and 2025?

Total longevity startup investment reached $8.49 billion across 331 deals in 2024, more than doubling from 2023's $3.82 billion according to industry tracking reports.

The first half of 2025 shows an estimated $5-6 billion in total investment, with Q1 2025 setting a $3.74 billion pace driven by mega-rounds like Altos Labs' $3 billion Series A. Mid-year funding typically accelerates with larger institutional rounds.

Discovery platforms attracted over $2.65 billion in 2024, representing the largest single category due to investor preference for foundational technologies that can address multiple aging mechanisms. Platform companies offer broader commercial potential than single-indication therapeutics.

Later-stage venture capital comprised 31% of total funding in 2024, indicating sector maturation as companies advance from research to clinical development. Seed and Series A deals remain critical for novel platforms entering the market.

Consumer health platforms and wearables contributed significantly to total volume, with ŌURA's $200 million Series D representing the commercialization trend within longevity investing beyond pure research plays.

What can be expected for longevity startup investment in 2026?

The longevity investment sector projects continued growth toward a $10 billion annual run-rate in 2026, driven by later-stage exits through IPOs and SPAC transactions creating liquidity for early investors.

Platform technologies and clinical-stage candidates will anchor investor confidence as the sector matures beyond early-stage hype toward execution-focused investments. Companies with validated platforms and clear regulatory pathways will command premium valuations.

Strategic partnerships between longevity startups and pharmaceutical giants will drive valuations and create new exit pathways. Corporate venture arms from major pharma companies will likely increase their longevity allocations as therapies approach commercialization.

Consumer health wearables and prevention platforms will attract non-traditional investors from consumer technology and fintech sectors, further diversifying the investor base and potentially reaching $12-15 billion in total market investment by 2026.

Regulatory clarity around longevity therapeutics and FDA pathways for aging-related indications will reduce investor risk and accelerate institutional capital deployment into the sector.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Conclusion

Sources

1. PR Newswire - Longevity Investment Report 2024
2. OpenVC - Biotech Investors List
3. Dealroom - Rubedo Life Sciences
4. Chemical & Engineering News - Rubedo Funding
5. GeekWire - Circulate Health Funding
6. Drug Discovery World - Junevity Funding
7. BioSpace - Minovia SPAC Deal
8. Gov Capital - Best Anti-Aging Startups
9. Longevity Technology - Annual Investment Report 2024
10. Business Wire - Rubedo Series A Announcement